09:51 AM EST, 11/07/2024 (MT Newswires) -- GoodRx ( GDRX ) shares were plunging early Thursday after the company reported Q3 results that improved year-over-year but trailed analyst projections and issued revenue guidance that lagged Wall Street expectations.

Q3 adjusted net income rose to $0.08 per diluted share from $0.06 a year earlier.

Analysts polled by Capital IQ expected $0.09.

Revenue for the quarter ended Sept. 30 was $195.3 million, compared with $180 million a year earlier.

Analysts surveyed by Capital IQ expected $195.7 million.

For Q4, the prescription discounts company is projecting revenue of around $200 million. Analysts are expecting revenue of $205.8 million.

Full-year revenue is expected at around $794 million. Analysts polled by Capital IQ are forecasting full-year sales of $800.7 million.

Price: 4.87, Change: -1.24, Percent Change: -20.29